The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a research study to test a drug that is already on the market with a population that was not included in the original clinical trials. Participants will be people over age 18 with HIV who are on antiretroviral therapy and have been diagnosed with MASLD.
Researchers will compare resmetirom to placebo (a look-alike substance that contains no drug) to see if resmetirom decreases the amount of fat in the liver.
Participants will:
* Complete 3 screening visits to determine eligibility. * Take resmetirom or placebo every day for 24 weeks if eligible. * Have 2 MRI scans to measure the amount of fat on the liver. One will be before treatment starts and one will be at the end of 24 weeks of treatment. * Attend 3 scheduled clinic visits while on treatment for bloodwork and safety assessments. * Participate in 3 phone calls while on treatment and one phone call 4 weeks after treatment is completed to check for safety and any health changes.
Adults (≥18 years of age) with documented HIV.
Documented diagnosis of MASLD established by imaging (ultrasound, CT scan or MRI) or vibration-controlled transient elastography (VCTE) or liver biopsy within 12 months before screening.
Hepatic fat fraction ≥8% by MRI-PDFF.
Liver stiffness by VCTE ≥8 kPa and CAP≥263 dB/m
History of significant alcohol consumption (defined as >2 drinks/day on average for men, >1 drinks/day on average for women) for at least 3 consecutive months (12 consecutive weeks) within 5 year before screening
History of other acute or chronic liver disease, including, but not limited to autoimmune, primary biliary cholangitis, Wilson's disease, alpha 1 antitrypsin deficiency, hemochromatosis, hepatitis B virus (HBV), and ongoing or recent (within the past 3 years) hepatitis C RNA positivity.
History of liver transplant.
Liver biopsy or radiologic imaging consistent with the clinical presence of cirrhosis or portal hypertension at screening.
Parallel
Resmetirom
DrugResmetirom - 80mg or 100mg based on participant weight
Placebo Control
DrugPlacebo - an identical looking tablet with no medicinal properties
Change from baseline in hepatic fat content at week 24
Proportion of participants with reduction of at least 30% in hepatic fat content from baseline to week 24
Change from baseline in liver enzyme parameters, lipid profile and fasting glucose
Click on the lead sponsor to view all of their trials.
Naga P. Chalasani
Lead sponsor
Indiana University
Sponsor institution
